Who is this relevant for?
- Manufacturers evaluating rare disease market entry
- R&D teams designing clinical trials for small populations
The FDA’s recent decision to allow single pivotal trial submissions for certain drug approvals signals a shift in regulatory flexibility. For rare disease programmes, this is not new. Developers have long worked with constraints that force innovation in trial design, evidence generation, and patient recruitment.
Rare diseases present structural challenges. Patient populations are often fewer than one in 100,000. Symptoms and disease progression vary widely. Many trials involve children, complicating randomisation. Recruitment is slow, patients are globally dispersed, and historical data is fragmented. In ultra-rare conditions, only a few hundred patients exist worldwide, meaning a trial may need to enrol a substantial proportion of the entire known population.
These conditions push developers to rethink traditional approaches. Advances in clinical data science, including AI and big data, are enabling new ways to generate evidence from smaller datasets. The FDA’s evolving stance on what constitutes regulatory-grade evidence reinforces this direction.
The implications for pharma operators are clear. Companies targeting rare diseases must build capabilities in flexible trial design, real-world evidence, and regulatory engagement. Those that can operate efficiently under these constraints will have an advantage in bringing therapies to patients with few options.